Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gu Mi

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|May 6, 2017
Enhancement of the adaptive signature design for learning and confirming in a single pivotal trialGu Mi
Plos One|April 8, 2015
The level of residual dispersion variation and the power of differential expression tests for RNA-Seq dataGu Mi, Yanming Di
Therapeutic Innovation & Regulatory Science|March 19, 2026
Advancing Platform Trials in Early Oncology by Using MATS and EXNEX in Randomized Controlled TrialsZhe Chen, Gu Mi, Ji Lin
Plos One|March 20, 2015
Goodness-of-fit tests and model diagnostics for negative binomial regression of RNA sequencing dataGu Mi, Yanming Di, Daniel W Schafer
Contemporary Clinical Trials|April 6, 2021
SPA: Single patient acceleration in oncology dose-escalation trialsGu Mi, Yuanyuan Bian, Xuejing Wang, et al.
Statistics in Medicine|June 7, 2024
A seamless phase II/III design with dose optimization for oncology drug developmentYuhan Li, Yiding Zhang, Gu Mi, et al.
Contemporary Clinical Trials|July 7, 2023
A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trialsZhenghao Jiang, Gu Mi, Ji Lin, et al.
BMC Proceedings|March 1, 2012
Power of association tests in the presence of multiple causal variantsYanming Di, Gu Mi, Luna Sun, et al.
Plos One|October 12, 2012
Length bias correction in gene ontology enrichment analysis using logistic regressionGu Mi, Yanming Di, Sarah Emerson, et al.
Therapeutic Innovation & Regulatory Science|July 1, 2026
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?Revathi Ananthakrishnan, Patrick Mitchell, Dong Xi, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|May 6, 2017
Enhancement of the adaptive signature design for learning and confirming in a single pivotal trialGu Mi
Plos One|April 8, 2015
The level of residual dispersion variation and the power of differential expression tests for RNA-Seq dataGu Mi, Yanming Di
Therapeutic Innovation & Regulatory Science|March 19, 2026
Advancing Platform Trials in Early Oncology by Using MATS and EXNEX in Randomized Controlled TrialsZhe Chen, Gu Mi, Ji Lin
Plos One|March 20, 2015
Goodness-of-fit tests and model diagnostics for negative binomial regression of RNA sequencing dataGu Mi, Yanming Di, Daniel W Schafer
Contemporary Clinical Trials|April 6, 2021
SPA: Single patient acceleration in oncology dose-escalation trialsGu Mi, Yuanyuan Bian, Xuejing Wang, et al.
Statistics in Medicine|June 7, 2024
A seamless phase II/III design with dose optimization for oncology drug developmentYuhan Li, Yiding Zhang, Gu Mi, et al.
Contemporary Clinical Trials|July 7, 2023
A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trialsZhenghao Jiang, Gu Mi, Ji Lin, et al.
BMC Proceedings|March 1, 2012
Power of association tests in the presence of multiple causal variantsYanming Di, Gu Mi, Luna Sun, et al.
Plos One|October 12, 2012
Length bias correction in gene ontology enrichment analysis using logistic regressionGu Mi, Yanming Di, Sarah Emerson, et al.
Therapeutic Innovation & Regulatory Science|July 1, 2026
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?Revathi Ananthakrishnan, Patrick Mitchell, Dong Xi, et al.
Pageof 2